Skip to main content
Top
Published in: Endocrine 1/2020

01-07-2020 | Hyperthyroidism | Original Article

Incidence and prevalence of hyperthyroidism: a population-based study in the Piedmont Region, Italy

Authors: Marina Caputo, Alessandro Pecere, Andrea Sarro, Chiara Mele, Andrealuna Ucciero, Loredana Pagano, Flavia Prodam, Gianluca Aimaretti, Paolo Marzullo, Francesco Barone-Adesi

Published in: Endocrine | Issue 1/2020

Login to get access

Abstract

Purpose

Unrecognized and untreated hyperthyroidism leads to serious clinical complications with adverse outcomes for patients and increasing costs for the health care system. Hence, adequate knowledge of the epidemiological features of such condition is desirable to plan effective interventions. The aim of our study was to estimate incidence and prevalence of hyperthyroidism in the mildly iodine-deficient Italian Region of Piedmont.

Methods

A retrospective cohort study was conducted using Administrative Health Databases of the Piedmont Region, Italy (2012–2018). Hyperthyroidism cases were defined as the subjects who had at least one of the following claims: (i) hospital discharge records with hyperthyroidism diagnosis code; (ii) exemption from co-payment for hyperthyroidism; (iii) prescription of one of the following medications: methimazole, propylthiouracil, or potassium perchlorate.

Results

The overall prevalence was 756 per 100,000 inhabitants [95% CI 748–764], and the overall incidence was 81 per 100,000-person year [95% CI 80–82]. The prevalence and incidence increased with age and were two-fold higher among women than men. Women also showed two distinct peaks in incidence at the age of 30 and 50; after the age of 60, the trend became similar between sexes. With regard to the geographic distribution, an increasing gradient of incidence was observed from the northern to the south-western areas of the Region.

Conclusion

This is the first Italian study based on health databases to estimate the incidence and prevalence of hyperthyroidism in the general population. This approach can represent an inexpensive and simple method to monitor patterns of hyperthyroidism in iodine-deficient areas.
Literature
1.
go back to reference M.P.J. Vanderpump, W.M.G. Tunbridge, J.M. French, D. Appleton, D. Bates, F. Clark, J. Grimley Evans, D.M. Hasan, H. Rodgers, F. Tunbridge, E.T. Young, The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. 43, 55–68 (1995)CrossRef M.P.J. Vanderpump, W.M.G. Tunbridge, J.M. French, D. Appleton, D. Bates, F. Clark, J. Grimley Evans, D.M. Hasan, H. Rodgers, F. Tunbridge, E.T. Young, The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. 43, 55–68 (1995)CrossRef
2.
go back to reference D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenlee, P. Laurberg, A.L. Maia, S.A. Rivkees, M. Samuels, J.A. Sosa, M.N. Stan, 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26, 1343–1421 (2016)CrossRef D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenlee, P. Laurberg, A.L. Maia, S.A. Rivkees, M. Samuels, J.A. Sosa, M.N. Stan, 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26, 1343–1421 (2016)CrossRef
3.
go back to reference J.V. Hennessey, J.R. Garber, K.A. Woeber, R. Cobin, I. Klein, American association of clinical endocrinologists and American college of endocrinology position statement on thyroid dysfunction case finding. Endocr. Pract. 22, 262–270 (2016)CrossRef J.V. Hennessey, J.R. Garber, K.A. Woeber, R. Cobin, I. Klein, American association of clinical endocrinologists and American college of endocrinology position statement on thyroid dysfunction case finding. Endocr. Pract. 22, 262–270 (2016)CrossRef
4.
go back to reference K.K. Miller, G.H. Daniels, Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin. Endocrinol. 55, 501–508 (2001)CrossRef K.K. Miller, G.H. Daniels, Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin. Endocrinol. 55, 501–508 (2001)CrossRef
5.
go back to reference S. Danzi, I. Klein, Thyroid hormone and the cardiovascular system. Med. Clin. N. Am. 96, 257–268 (2012)CrossRef S. Danzi, I. Klein, Thyroid hormone and the cardiovascular system. Med. Clin. N. Am. 96, 257–268 (2012)CrossRef
6.
go back to reference B. Biondi, G.J. Kahaly, Cardiovascular involvment in patients with different causes of hyperthyroidism. Nat. Rev. Endocrinol. 6, 431–443 (2010)CrossRef B. Biondi, G.J. Kahaly, Cardiovascular involvment in patients with different causes of hyperthyroidism. Nat. Rev. Endocrinol. 6, 431–443 (2010)CrossRef
7.
go back to reference J.V. Parle, P. Maisonneuve, M.C. Sheppard, P. Boyle, J.A. Franklyn, Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358, 861–865 (2001)CrossRef J.V. Parle, P. Maisonneuve, M.C. Sheppard, P. Boyle, J.A. Franklyn, Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358, 861–865 (2001)CrossRef
8.
go back to reference Y. Ono, S. Ono, H. Yasunaga, H. Matsui, K. Fushimi, Y. Tanaka, Factors associated with mortality of thyroid storm: analysis using a national inpatient database in Japan. Medicine 95, e2848 (2016)CrossRef Y. Ono, S. Ono, H. Yasunaga, H. Matsui, K. Fushimi, Y. Tanaka, Factors associated with mortality of thyroid storm: analysis using a national inpatient database in Japan. Medicine 95, e2848 (2016)CrossRef
9.
go back to reference A.P. Delitala, M.G. Pilia, L. Ferreli, F. Loi, L. Balaci, D. Schlessinger, F. Cucca, E. Medicine, Prevalence of unknown thyroid disorders in a Sardinian cohort. Eur. J. Endocrinol. 171, 143–149 (2015)CrossRef A.P. Delitala, M.G. Pilia, L. Ferreli, F. Loi, L. Balaci, D. Schlessinger, F. Cucca, E. Medicine, Prevalence of unknown thyroid disorders in a Sardinian cohort. Eur. J. Endocrinol. 171, 143–149 (2015)CrossRef
10.
go back to reference P.N. Taylor, D. Albrecht, A. Scholz, G. Gutierrez-buey, J.H. Lazarus, C.M. Dayan, O.E. Okosieme, Global epidemiology of hyperthyroidism and hypothyroidism. Nat. Rev. Endocrinol. 14, 301–316 (2018)CrossRef P.N. Taylor, D. Albrecht, A. Scholz, G. Gutierrez-buey, J.H. Lazarus, C.M. Dayan, O.E. Okosieme, Global epidemiology of hyperthyroidism and hypothyroidism. Nat. Rev. Endocrinol. 14, 301–316 (2018)CrossRef
11.
go back to reference J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer, L.E. Braverman, Serum TSH, T 4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 87, 489–499 (2002)CrossRef J.G. Hollowell, N.W. Staehling, W.D. Flanders, W.H. Hannon, E.W. Gunter, C.A. Spencer, L.E. Braverman, Serum TSH, T 4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 87, 489–499 (2002)CrossRef
12.
go back to reference A.G. Madariaga, S.S. Palacios, F. Guillén-grima, J.C. Galofré, The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J. Clin. Endocrinol. Metab. 99, 923–931 (2014)CrossRef A.G. Madariaga, S.S. Palacios, F. Guillén-grima, J.C. Galofré, The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J. Clin. Endocrinol. Metab. 99, 923–931 (2014)CrossRef
13.
go back to reference A. Asban, S.K. Chung, M.A. Tresler, P. Huilgol, R. Xie, J.K. Kirklin, C.J. Balentine, B.M. Lindeman, H. Chen, Hyperthyroidism is underdiagnosed and undertreated in 3336 patients: an opportunity for improvement and intervention. Ann. Surg. 268, 506–512 (2018)CrossRef A. Asban, S.K. Chung, M.A. Tresler, P. Huilgol, R. Xie, J.K. Kirklin, C.J. Balentine, B.M. Lindeman, H. Chen, Hyperthyroidism is underdiagnosed and undertreated in 3336 patients: an opportunity for improvement and intervention. Ann. Surg. 268, 506–512 (2018)CrossRef
14.
go back to reference M. Caputo, A. Ucciero, C. Mele, L. De Marchi, C. Magnani, T. Cena, P. Marzullo, F. Barone-Adesi, G. Aimaretti, Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region, Italy. J. Endocrinol. Investig. 42, 397–402 (2018)CrossRef M. Caputo, A. Ucciero, C. Mele, L. De Marchi, C. Magnani, T. Cena, P. Marzullo, F. Barone-Adesi, G. Aimaretti, Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region, Italy. J. Endocrinol. Investig. 42, 397–402 (2018)CrossRef
15.
go back to reference C.B. Giorda, P. Carnà, F. Romeo, G. Costa, B. Tartaglino, R. Gnavi, Prevalence, incidence and associated comorbidities of treated hypothyroidism: an update from a European population. Eur. Soc. Endocrinol. 176, 533–542 (2017)CrossRef C.B. Giorda, P. Carnà, F. Romeo, G. Costa, B. Tartaglino, R. Gnavi, Prevalence, incidence and associated comorbidities of treated hypothyroidism: an update from a European population. Eur. Soc. Endocrinol. 176, 533–542 (2017)CrossRef
16.
go back to reference F. Brandt, M. Thvilum, D. Almind, K. Christensen, A. Green, T.H. Brix, Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS ONE 8, 1–6 (2013) F. Brandt, M. Thvilum, D. Almind, K. Christensen, A. Green, T.H. Brix, Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS ONE 8, 1–6 (2013)
17.
go back to reference A. Olivieri, P. Vitti (eds). Attività di monitoraggio del programma nazionale per la prevenzione dei disordini da carenza iodica. Roma: Istituto Superiore di Sanità (2014). (Rapporti ISTISAN 14/6) A. Olivieri, P. Vitti (eds). Attività di monitoraggio del programma nazionale per la prevenzione dei disordini da carenza iodica. Roma: Istituto Superiore di Sanità (2014). (Rapporti ISTISAN 14/6)
18.
go back to reference P. Laurberg, C. Cerqueira, L. Ovesen, L.B. Rasmussen, H. Perrild, S. Andersen, I.B. Pedersen, A. Carlé, Iodine intake as a determinant of thyroid disorders in populations. Best Pract. Res. Clin. Endocrinol. Metab. 24, 13–27 (2010)CrossRef P. Laurberg, C. Cerqueira, L. Ovesen, L.B. Rasmussen, H. Perrild, S. Andersen, I.B. Pedersen, A. Carlé, Iodine intake as a determinant of thyroid disorders in populations. Best Pract. Res. Clin. Endocrinol. Metab. 24, 13–27 (2010)CrossRef
19.
go back to reference A. Olivieri, C. Di Cosmo, S. De Angelis, R. Da Cas, P. Stacchini, A. Pastorelli, P. Vitti, The way forward in Italy for iodine. Minerva Med. 108, 159–168 (2017)PubMed A. Olivieri, C. Di Cosmo, S. De Angelis, R. Da Cas, P. Stacchini, A. Pastorelli, P. Vitti, The way forward in Italy for iodine. Minerva Med. 108, 159–168 (2017)PubMed
20.
go back to reference F. Aghini-lombardi, L. Antonangeli, E. Martino, P. Vitti, D. Maccherini, F. Leoli, T. Rago, L. Grasso, R. Valeriano, A. Balestrieri, The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J. Clin. Endocrinol. Metab. 84, 561–566 (1999)PubMed F. Aghini-lombardi, L. Antonangeli, E. Martino, P. Vitti, D. Maccherini, F. Leoli, T. Rago, L. Grasso, R. Valeriano, A. Balestrieri, The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J. Clin. Endocrinol. Metab. 84, 561–566 (1999)PubMed
21.
go back to reference F. Alghini Lombardi, E. Fiore, M. Tonacchera, L. Antonangeli, T. Rago, M. Frigeri, A.M. Provenazle, L. Montanelli, L. Grasso, A. Pinchera, P. Vitti, The effect of voluntary iodine prophylaxis in a small rural community: the Pescopagano survey 15 years later. J. Clin. Endocrinol. Metab. 98, 1031–1039 (2013)CrossRef F. Alghini Lombardi, E. Fiore, M. Tonacchera, L. Antonangeli, T. Rago, M. Frigeri, A.M. Provenazle, L. Montanelli, L. Grasso, A. Pinchera, P. Vitti, The effect of voluntary iodine prophylaxis in a small rural community: the Pescopagano survey 15 years later. J. Clin. Endocrinol. Metab. 98, 1031–1039 (2013)CrossRef
22.
go back to reference A. Costa, O. Brambati Testori, G. Cenderelli, Dati sulla endemia di gozzo in Piemonte. G. Accad. Med. 137, 44–61 (1974) A. Costa, O. Brambati Testori, G. Cenderelli, Dati sulla endemia di gozzo in Piemonte. G. Accad. Med. 137, 44–61 (1974)
23.
go back to reference L. Bartalena, E. Masiello, F. Magri, G. Veronesi, E. Bianconi, F. Zerbini, M. Gaiti, E. Spreafico, D. Gallo, P. Premoli, E. Piantanida, M.L. Tanda, M. Ferrario, P. Vitti, L. Chiovato, The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J. Endocrinol. Investig. 39, 1445–1451 (2016)CrossRef L. Bartalena, E. Masiello, F. Magri, G. Veronesi, E. Bianconi, F. Zerbini, M. Gaiti, E. Spreafico, D. Gallo, P. Premoli, E. Piantanida, M.L. Tanda, M. Ferrario, P. Vitti, L. Chiovato, The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study. J. Endocrinol. Investig. 39, 1445–1451 (2016)CrossRef
24.
go back to reference M. Gizak. Global scorecard 2016: moving toward optimal iodine status. Iodine Glob. Netw. 44, 6–9 (2016) M. Gizak. Global scorecard 2016: moving toward optimal iodine status. Iodine Glob. Netw. 44, 6–9 (2016)
25.
go back to reference E. Saggiorato, F. Arecco, A. Mussa, C. Sacerdote, R. Rossetto, C. Origlia, L. Germano, D. Deandreis, F. Orlandi, Goiter prevalence and urinary iodine status in urban and rural/mountain areas of Piedmont region. J. Endocrinol. Investig. 29, 67–73 (2006)CrossRef E. Saggiorato, F. Arecco, A. Mussa, C. Sacerdote, R. Rossetto, C. Origlia, L. Germano, D. Deandreis, F. Orlandi, Goiter prevalence and urinary iodine status in urban and rural/mountain areas of Piedmont region. J. Endocrinol. Investig. 29, 67–73 (2006)CrossRef
26.
go back to reference F. Cubadda, S. Ciardullo, M. D’Amato, A. Raggi, F. Aureli, M. Carcea, Arsenic contamination of the environment-food chain: a survey on wheat as a test plant to investigate phytoavailable arsenic in italian agricultural soils and as a source of inorganic arsenic in the diet. J. Agric. Food Chem. 58, 10176–10183 (2010)CrossRef F. Cubadda, S. Ciardullo, M. D’Amato, A. Raggi, F. Aureli, M. Carcea, Arsenic contamination of the environment-food chain: a survey on wheat as a test plant to investigate phytoavailable arsenic in italian agricultural soils and as a source of inorganic arsenic in the diet. J. Agric. Food Chem. 58, 10176–10183 (2010)CrossRef
27.
go back to reference E. Gaitan, Goitrogens in food and water. Annu. Rev. Nutr. 10, 21–39 (1990)CrossRef E. Gaitan, Goitrogens in food and water. Annu. Rev. Nutr. 10, 21–39 (1990)CrossRef
28.
go back to reference H. Martínez-Salgado, R. Castañeda-Limones, D. Lechuga-Martín Del Campo, R.I. Ramos-Hernández, M. Orozco-López, J. Rivera-Dommarco, I. Mendoza, C. Magos, Iodine deficiency and other goitrogens in the persistence of endemic goiter in Mexico. Gac. Med. Mex 138, 149–156 (2002)PubMed H. Martínez-Salgado, R. Castañeda-Limones, D. Lechuga-Martín Del Campo, R.I. Ramos-Hernández, M. Orozco-López, J. Rivera-Dommarco, I. Mendoza, C. Magos, Iodine deficiency and other goitrogens in the persistence of endemic goiter in Mexico. Gac. Med. Mex 138, 149–156 (2002)PubMed
29.
go back to reference M. Abraham-Nordling, K. Byström, O. Törring, M. Lantz, G. Berg, J. Calissendorff, H.F. Nyström, S. Jansson, G. Jörneskog, F. Karlsson, E. Nyström, H. Ohrling, T. Örn, B. Hallengren, G. Wallin, Incidence of hyperthyroidism in Sweden. Eur. J. Endocrinol. 165, 899–905 (2011)CrossRef M. Abraham-Nordling, K. Byström, O. Törring, M. Lantz, G. Berg, J. Calissendorff, H.F. Nyström, S. Jansson, G. Jörneskog, F. Karlsson, E. Nyström, H. Ohrling, T. Örn, B. Hallengren, G. Wallin, Incidence of hyperthyroidism in Sweden. Eur. J. Endocrinol. 165, 899–905 (2011)CrossRef
30.
go back to reference J.l. Wémeau, M. Klein, J.L. Sadoul, C. Briet, F.L. Vélayoudom-Céphise, Graves’ disease: introduction, epidemiology, endogenous and environmental pathogenic factors. Ann. Endocrinol. 79, 599–607 (2018)CrossRef J.l. Wémeau, M. Klein, J.L. Sadoul, C. Briet, F.L. Vélayoudom-Céphise, Graves’ disease: introduction, epidemiology, endogenous and environmental pathogenic factors. Ann. Endocrinol. 79, 599–607 (2018)CrossRef
31.
go back to reference M.P.J. Vanderpump, The epidemiology of thyroid disease. Br. Med. Bull. 99, 39–51 (2011)CrossRef M.P.J. Vanderpump, The epidemiology of thyroid disease. Br. Med. Bull. 99, 39–51 (2011)CrossRef
32.
go back to reference G. Trifirò, R. Gini, F. Barone-Adesi, E. Beghi, A. Cantarutti, A. Capuano, C. Carnovale, A. Clavenna, M. Dellagiovanna, C. Ferrajolo, M. Franchi, Y. Ingrasciotta, U. Kirchmayer, F. Lapi, R. Leone, O. Leoni, E. Lucenteforte, U. Moretti, A. Mugelli, L. Naldi, E. Poluzzi, C. Rafaniello, F. Rea, J. Sultana, M. Tettamanti, G. Traversa, A. Vannacci, L. Mantovani, G. Corrao, The role of European healthcare databases for post-marketing drug effectiveness, safety and value evaluation: where does Italy stand? Drug Saf. 42, 347–363 (2019)CrossRef G. Trifirò, R. Gini, F. Barone-Adesi, E. Beghi, A. Cantarutti, A. Capuano, C. Carnovale, A. Clavenna, M. Dellagiovanna, C. Ferrajolo, M. Franchi, Y. Ingrasciotta, U. Kirchmayer, F. Lapi, R. Leone, O. Leoni, E. Lucenteforte, U. Moretti, A. Mugelli, L. Naldi, E. Poluzzi, C. Rafaniello, F. Rea, J. Sultana, M. Tettamanti, G. Traversa, A. Vannacci, L. Mantovani, G. Corrao, The role of European healthcare databases for post-marketing drug effectiveness, safety and value evaluation: where does Italy stand? Drug Saf. 42, 347–363 (2019)CrossRef
33.
go back to reference C. Mazzali, P. Duca, Use of administrative data in healthcare research. Intern. Emerg. Med. 10, 517–524 (2015)CrossRef C. Mazzali, P. Duca, Use of administrative data in healthcare research. Intern. Emerg. Med. 10, 517–524 (2015)CrossRef
34.
go back to reference M. Bouga, M.E.J. Lean, E. Combet, Contemporary challenges to iodine status and nutrition: the role of foods, dietary recommendations, fortification and supplementation. Proc. Nutr. Soc. 77, 302–313 (2018)CrossRef M. Bouga, M.E.J. Lean, E. Combet, Contemporary challenges to iodine status and nutrition: the role of foods, dietary recommendations, fortification and supplementation. Proc. Nutr. Soc. 77, 302–313 (2018)CrossRef
35.
go back to reference F. Magri, F. Zerbini, M. Gaiti, V. Capelli, L. Croce, S. Bini, A.E. Rigamonti, G. Fiorini, S.G. Cella, L. Chiovato, Poverty and immigration as a barrier to iodine intake and maternal adherence to iodine supplementation. J. Endocrinol. Investig. 42, 435–442 (2019)CrossRef F. Magri, F. Zerbini, M. Gaiti, V. Capelli, L. Croce, S. Bini, A.E. Rigamonti, G. Fiorini, S.G. Cella, L. Chiovato, Poverty and immigration as a barrier to iodine intake and maternal adherence to iodine supplementation. J. Endocrinol. Investig. 42, 435–442 (2019)CrossRef
Metadata
Title
Incidence and prevalence of hyperthyroidism: a population-based study in the Piedmont Region, Italy
Authors
Marina Caputo
Alessandro Pecere
Andrea Sarro
Chiara Mele
Andrealuna Ucciero
Loredana Pagano
Flavia Prodam
Gianluca Aimaretti
Paolo Marzullo
Francesco Barone-Adesi
Publication date
01-07-2020
Publisher
Springer US
Keyword
Hyperthyroidism
Published in
Endocrine / Issue 1/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-020-02222-7

Other articles of this Issue 1/2020

Endocrine 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine